In response to a study published online in the BMJ, comparing the performance of two cardiovascular risk assessment tools, British Heart Foundation (BHF) Medical Director, Professor Peter Weissberg, said: "The comparison made here between QRISK and the Framingham risk assessment tool shows that QRISK performs better in the UK population. This suggests that in the future we should be using QRISK as the model for assessing a person's cardiovascular risk. "However, perhaps the most telling finding in the report was the indication that only a very small percentage of the UK population have undergone any formal risk assessment. Rather than agonise over which assessment tool is best, we should be urging people to visit their GP and have a heart health check.
Scientists at the European Molecular Biology Laboratory (EMBL) and the University of Heidelberg, Germany, have come a step closer to understanding how cholesterol levels are regulated. In a study published in the journal Cell Metabolism, the researchers identified 20 genes that are involved in this process. Besides giving scientists a better idea of where to look to uncover the mechanisms that ensure cholesterol balance is maintained, the discovery could lead to new treatments for cholesterol-related diseases. "This finding may open new avenues for designing targeted therapies, for example by looking for small molecules that could impact these genes, " says Heiko Runz, whose group at the University Clinic Heidelberg carried out the research together with Rainer Pepperkok's lab at EMBL.
Atrium Medical is pleased to announce that is has received CE Mark for a new generation Cobalt Chromium Coronary Stent System called Cinatra™ . Cinatra™ is indicated for the treatment of coronary artery occlusive disease. Atrium is excited to release this best in class Cobalt Chromium Coronary Stent System that is extremely low in profile, ultra flexible, and highly deliverable. In an independent lab test, Atrium's new Cinatra™ CoCr Stent was highlighted as having the lowest crossing profile and greatest flexibility when compared to the leading competitors.* The advanced design of the Cinatra™ CoCr Stent with its superior mechanical properties have produced excellent clinical results yielding a very low late lumen loss.
Even though it may sound like it, heart failure does not necessarily mean that the heart has failed. Heart failure is a serious condition in which the heart is not pumping blood around the body efficiently. The patient's left side, right side, or even both sides of the body can be affected. Symptoms will depend on which side is affected and how severe the heart failure is - symptoms can be severe. According to Medilexicon's medical dictionary, heart failure is "1. inadequacy of the heart so that as a pump it fails to maintain the circulation of blood, with the result that congestion and edema develop in the tissues; 2. resulting clinical syndromes include shortness of breath, pitting or nonpitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales in various combinations.
Cardiovascular diseases (CVD) are the main cause of early death and disability in Europe, accounting each year for the loss of more than 2 million lives and costing the EU economy an estimated 192 billion euros. Top level stakeholders and EU and national policymakers are meeting in Brussels to assess current prevention programs and to develop a strategy for Cardiovascular Health. The one day conference, organised by the European Heart Network and the European Society of Cardiology, is part of Work Package 5 of the EuroHeart Project. New research will be presented at the conference, which highlights striking differences across different countries in Europe both in terms of national prevention policies and cardiovascular mortality.
ERT (Nasdaq: ERES), a leading provider of centralized ECG, ePRO, eClinical technology and other services to the biopharmaceutical, medical device and related industries, announced today the launch of a unique online web interface - My Study Portal(TM). Following the successful launch of ERT's new website, My Study Portal is aimed at enhancing the accuracy and efficiency of cardiac safety data management in clinical trials. My Study Portal, which replaces the previous Digital ECG Community, is an easy to use web-based portal which provides users with secure 24/7 access to a centralized environment to view and manage vital data, from anywhere in the world -- on demand, in real time.